124
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon & show all
Pages 235-242 | Published online: 30 Mar 2020

References

  • Nelson AL. Extended-cycle oral contraception: a new option for routine use. Treat Endocrinol. 2005;4(3):139–145. doi:10.2165/00024677-200504030-00002
  • den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59(6):357–362. doi:10.1016/S0010-7824(99)00043-8
  • Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68(2):89–96. doi:10.1016/S0010-7824(03)00141-0
  • Edelman A, Gallo MF, Jensen JT, Nichols MD, Grimes DA. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2011;8:CD004695.
  • Seidman DS, Yeshaya A, Ber A, et al. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone. Isr Med Assoc J. 2010;12(7):400–405.
  • Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D; Yasmin Extended Regimen Study Group. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception. 2006;73(1):34–40. doi:10.1016/j.contraception.2005.06.068
  • Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67(1):9–13. doi:10.1016/S0010-7824(02)00445-6
  • Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006;74(6):439–445. doi:10.1016/j.contraception.2006.07.005
  • Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception. 2004;70(5):365–370. doi:10.1016/j.contraception.2004.06.001
  • Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception. 2010;81(3):215–222. doi:10.1016/j.contraception.2009.10.010
  • Machado RB, Pompei LM, Badalotti M, et al. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2017;22(1):11–16. doi:10.1080/13625187.2016.1239077
  • World Health Organization. Medical Eligibility Criteria for Contraceptive Use [Internet]. 5th. Geneva: WHO; 2015. [cited February 14, 2018]. Available from: http://whqlibdoc.who.int/publications/2015/9789241563888_eng.pdf. Accessed March 12, 2020.
  • Freeman E, DeRubeis RJ, Rickelsa K. Reliability and validity of a daily diary for premenstrual syndrome. Psyc Res. 1996;65(2):97–106. doi:10.1016/S0165-1781(96)02929-0
  • Belsey EM, Machin D, d’Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34(3):253–260. doi:10.1016/0010-7824(86)90006-5
  • Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study. Contraception. 2012;86(2):110–118. doi:10.1016/j.contraception.2011.12.009
  • Klipping C, Duijkers I, Fortier MP, Marr J, Trummer D, Elliesen J. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care. 2012;38(2):73–83. doi:10.1136/jfprhc-2011-100213
  • Hitchcock CL, Prior JC. Evidence about extending the duration of oral contraceptive use to suppress menstruation. Womens Health Issues. 2004;14(6):201–211. doi:10.1016/j.whi.2004.08.005
  • Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol. 2006;195(4):935–941. doi:10.1016/j.ajog.2006.02.048